Chronic learning and memory problems that plague patients with schizophrenia may have a worthy foe in a monoclonal antibody that also holds promise in the fight against cancer and is already used to treat a rare disorder …

Follow this link: 

Monoclonal antibody holds promise of reducing learning, memory …